Voyager Therapeutics (NASDAQ:VYGR) Price Target Cut to $8.00 by Analysts at Wedbush

Key Points

• Wedbush has lowered its price target for Voyager Therapeutics from $9.00 to $8.00, while maintaining an "outperform" rating, suggesting a potential upside of 138.81% from the last closing price.
• Despite the recent price target reduction, Voyager Therapeutics reported a quarterly earnings miss, with an EPS of ($0.57) against an expected ($0.48) and revenue of $5.20 million, which fell short of the $9.50 million forecast.
• Institutional investors own approximately 48.03% of Voyager Therapeutics’ stock, with several hedge funds acquiring new stakes during the second quarter.

Voyager Therapeutics (NASDAQ:VYGR - Free Report) had its price target trimmed by Wedbush from $9.00 to $8.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

Voyager Therapeutics Trading Down 2.5%

NASDAQ VYGR traded down $0.08 during trading on Thursday, hitting $3.14. The company had a trading volume of 1,225,068 shares, compared to its average volume of 781,033. Voyager Therapeutics has a one year low of $2.64 and a one year high of $8.27. The company has a market cap of $174.18 million, a price-to-earnings ratio of -1.70 and a beta of 0.90. The company's fifty day moving average is $3.23 and its 200-day moving average is $3.63.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. The company had revenue of $5.20 million during the quarter, compared to the consensus estimate of $9.50 million. As a group, equities analysts anticipate that Voyager Therapeutics will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VYGR. Cubist Systematic Strategies LLC bought a new position in Voyager Therapeutics in the fourth quarter worth $29,000. Tower Research Capital LLC TRC raised its holdings in Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after purchasing an additional 3,077 shares in the last quarter. CWM LLC increased its stake in shares of Voyager Therapeutics by 856.3% in the 1st quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after acquiring an additional 9,376 shares in the last quarter. Oxford Asset Management LLP bought a new position in shares of Voyager Therapeutics in the 4th quarter worth about $60,000. Finally, Bank of Montreal Can bought a new position in shares of Voyager Therapeutics in the 2nd quarter worth about $36,000. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.